A Phase 2 Study of AZD6244 in Relapsed or Refractory AML
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2015
At a glance
- Drugs Selumetinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 04 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Aug 2012 Planned End Date changed from 1 Jun 2008 to 1 Dec 2012 as reported by ClinicalTrials.gov.